BioSpace News Archive

KemPharm, Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that its president and chief executive officer, Travis C.

Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference.

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced it will participate in the following September investor conferences, which will each be held in a virtual meeting format:

Personalis, Inc., a leader in advanced genomics for cancer, announced that company management will participate in the following upcoming investor conferences.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that on September 2, 2020 the Supreme Court of the State of New York, New York County (the “Court”) has dismissed with prejudice Platinum-Montaur Life Sciences LLC’s (“Platinum-Montaur”) law suit against the Company.

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr. Eduard Holdener.

- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference as follows: Date: Thursday, September 10, 2020 Time: 11:20 a.m. Eastern Time Webcast: https://metroconnections.zoom.us/webinar/regis

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced it will host a “PTG-300 Opportunity Update” webinar on Friday, Sept. 11, 2020 , from 12 p.m. to 1:30 p.m. EDT . The event will feature presentations on clinical needs in polycythemia vera and market research on the potential opportunity for PTG-300. Members o

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Webcast information when available will be posted in the Investor Relations section of the Company’s website at https://www.cellectis.com/en/investors/events-and-webcasts/ Citi Annual BioPharma Conferen

Compassionate-use study supports continued development of IONIS-PKK-LRx as an experimental treatment to reduce acute attacks of hereditary angioedema